Regulatory Health Canada approves Biocon’s two denosumab biosimilars Pharmaceutical TechnologyBiocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.RegulatoryRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively. RegulatoryRead full story Post navigation Previous: Tortugas debuts with $106M and brain drugs from Hansoh, EisaiNext: Medicare obesity drug pilot extended after insurer pushback Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
